RxDoctor Payments Data

Daniel Colon-Conde, MD

Pain Medicine · Lawrenceville, GANPI 1962898031

Payments from drug & device makers

$5,291in general payments, 2019–2025

Across 131 payments — averaging $40.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$983
  • Collegium Pharmaceutical, Inc.$387
  • Nevro Corp.$379
  • Stimwave Technologies Incorporated$272
  • Curonix LLC$246
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$91517%
  • Food & beverage$4,37683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,291 in reported general payments places this provider in the 65th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$114,726
Medicare patients
446
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl88$60,589
RelistorMethylnaltrexone Bromide17$43,662
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen898$39,771
Buprenorphine121$31,917
NucyntaTapentadol Hcl19$16,243
MovantikNaloxegol Oxalate35$15,084
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen668$13,454
Xtampza ErOxycodone Myristate19$9,085
Pregabalin319$6,213
ZtlidoLidocaine14$5,967
Oxycodone Hcl292$5,277
Tramadol Hcl ErTramadol Hcl61$4,364
Lidocaine45$3,451
Diclofenac Sodium146$3,227
Gabapentin326$3,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Xtampza Er$387$85,917126 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$158$43,66217 claims
Scilex Pharmaceuticals Inc.Ztlido$173$5,96714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →